Ymmunobio signs collaboration agreement with YUMAB

Riehen, Switzerland, June 14, 2022 – Ymmunobio AG a preclinical stage biotech
company specializing in the development of CEACAM (carcinoembryonic antigen-related cell
adhesion molecules) antibodies as anti-cancer treatments has signed a collaboration agreement with YUMAB for antibody based drug development projects.

Read Ymmunobio’s press release

Contact

YUMAB GmbH
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
Email: info@yumab.com

Ymmunobio AG
Dr. Katrin Rupalla
info@ymmuno.bio